Update on Sjögren's syndrome : Diagnostics, treatment, and challenges
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Sjögren's syndrome (SjS) is the most common connective tissue disease with a prevalence of 1:200. Predominantly affecting women, SjS is associated with destruction of the exocrine glands, leading to xerophthalmia and xerostomia. In over 50% of patients, there are also extraglandular manifestations, leading to multiple organ manifestations including polyneuropathies and interstitial lung disease as well as symptoms such as fatigue and arthralgia. Diagnostic procedures include biomarkers, in particular anti-SS-A/Ro antibodies, histology of salivary glands, and salivary gland sonography. There are currently no licensed immunosuppressive drugs for SjS, so current treatment is often based on off-label use of drugs. The European League Against Rheumatism (EULAR) has recently published treatment recommendations based on the prevailing organ manifestations. Several promising controlled trials with novel compounds and concepts are currently in progress.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Zeitschrift fur Rheumatologie - 83(2024), 3 vom: 28. März, Seite 217-228 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Update Sjögren-Syndrom : Diagnostik, Therapie und Fallstricke |
|---|
| Beteiligte Personen: |
Zehrfeld, Nadine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologics |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00393-024-01493-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369878329 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369878329 | ||
| 003 | DE-627 | ||
| 005 | 20240329000847.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00393-024-01493-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM369878329 | ||
| 035 | |a (NLM)38498147 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Zehrfeld, Nadine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Update on Sjögren's syndrome |b Diagnostics, treatment, and challenges |
| 246 | 3 | 3 | |a Update Sjögren-Syndrom : Diagnostik, Therapie und Fallstricke |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Sjögren's syndrome (SjS) is the most common connective tissue disease with a prevalence of 1:200. Predominantly affecting women, SjS is associated with destruction of the exocrine glands, leading to xerophthalmia and xerostomia. In over 50% of patients, there are also extraglandular manifestations, leading to multiple organ manifestations including polyneuropathies and interstitial lung disease as well as symptoms such as fatigue and arthralgia. Diagnostic procedures include biomarkers, in particular anti-SS-A/Ro antibodies, histology of salivary glands, and salivary gland sonography. There are currently no licensed immunosuppressive drugs for SjS, so current treatment is often based on off-label use of drugs. The European League Against Rheumatism (EULAR) has recently published treatment recommendations based on the prevailing organ manifestations. Several promising controlled trials with novel compounds and concepts are currently in progress | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biologics | |
| 650 | 4 | |a Biopsy | |
| 650 | 4 | |a Cardiovascular risk | |
| 650 | 4 | |a Salivary gland | |
| 650 | 4 | |a Sicca syndrome | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Witte, Torsten |e verfasserin |4 aut | |
| 700 | 1 | |a Ernst, Diana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zeitschrift fur Rheumatologie |d 1974 |g 83(2024), 3 vom: 28. März, Seite 217-228 |w (DE-627)NLM000024287 |x 1435-1250 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2024 |g number:3 |g day:28 |g month:03 |g pages:217-228 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00393-024-01493-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2024 |e 3 |b 28 |c 03 |h 217-228 | ||